# NAPS: Niacin for Parkinson's Disease

> **NIH VA I01** · CHARLIE NORWOOD VA MEDICAL CENTER · 2021 · —

## Abstract

PROJECT SUMMARY/ABSTRACT
We are the first group to demonstrate chronic vitamin B3 (niacin and niacinamide) deficiency in individuals with
Parkinson's disease (PD). Niacin and niacinamide are the source of NAD which supplies energy and DNA
repair to every cell in the body. PD patients frequently report symptoms which we believe are related to the
vitamin deficiency, including daytime fatigue, sleep dysfunction and low-level mood.
In addition, niacin but not niacinamide acts on GPR109A, an anti-inflammatory receptor. We are also the first
group to show elevated GPR109A levels in the white blood cells (macrophages) and substantia nigra of PD
patients, providing additional evidence of the consequences of chronic niacin deficiency in PD.
In this exploratory trial, we propose to provide over-the-counter nutritional supplementation to test the
hypothesis that correcting the deficiency via niacin's dual actions (energy supply and anti-inflammation) will
improve symptom outcomes and reduce inflammation better than niacinamide.
Aim 1. To determine whether niacin supplementation will reduce inflammation and improve the
symptoms of PD patients better than niacinamide.
 Aim 2. To determine whether macrophage polarization and mitochondrial boost will reflect niacin and
niacinamide supplementation independently.
We will accomplish these aims with a two-arm double blind, randomized, fixed-dose, parallel niacinamide-
controlled intention-to-treat 18-month pre-post prospective cohort design with mid-point assessment.
The primary endpoint of this trial will be a decrease in the severity of motor symptoms as assessed by the
Unified Parkinson's Disease Rating Scale Motor Section (UPDRS III). Secondary endpoints include wearable-
technology measurements to document improvements in balance control and cognitive functions including
nightsleep and executive control, as well as increased glycolysis and decreased GPR109A levels.

## Key facts

- **NIH application ID:** 9872019
- **Project number:** 5I01CX001815-02
- **Recipient organization:** CHARLIE NORWOOD VA MEDICAL CENTER
- **Principal Investigator:** Chandramohan Wakade
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2021
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2019-04-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9872019

## Citation

> US National Institutes of Health, RePORTER application 9872019, NAPS: Niacin for Parkinson's Disease (5I01CX001815-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9872019. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*